Africa

A study of Africa’s current and planned vaccine manufacturing capacity offers insights into how to target investments and development efforts to promote long-term success.

New analysis illuminates strengths, gaps, opportunities, and recommendations for building a sustainable vaccine manufacturing ecosystem.

This briefing paper describes a study to assess the current and planned state of vaccine manufacturing capacity in Africa, and provides insights into what is needed to develop a robust and sustainable vaccine manufacturing ecosystem. African vaccine manufacturing is set to expand dramatically as the continent works to safeguard itself against future pandemics and disease outbreaks—but with so many new projects on the horizon, a clear picture of gaps and needs is necessary to ensure all stakeholders are aligned and investments can succeed. This research can help stakeholders, governments, and funders better coordinate and prioritize development efforts, interventions, and investments.

Less than two years since the establishment of the African Medicines Agency (AMA), Kenya officially deposited its ratification instruments to the African Union Commission on 16 July 2023.

This year's annual report features our annual financial overview, a list of PATH's funders and supporters, and our accomplishments in 2022.

Policies that build strong primary health care systems are essential to advancing health equity— but they are complex and difficult to design. PATH created the PHC in Policies Tracker as a consolidated source of information to equip stakeholders including policymakers, advocates, implementers, and donors with information about existing policies that shape PHC systems. This new virtual public dashboard tool maps and analyzes data about national-level health policy documents relevant to primary health care (PHC) in 26 low- and middle- income countries—comparing content of these policies with recommendations laid out in key global-level guidance frameworks such as the WHO PHC Monitoring Framework and Indicators (MFI). The tracker aims to improve understanding of policies for PHC in LMICs, add to the global conversation about how to design robust policy for PHC, and help users identify high-impact opportunities for action toward better health for all. This brief provides an overview of the findings and key takeaways from the tracker project, as well as information about methodology and limitations. Access the tracker at bit.ly/PHC_policy_tracker

This fact sheet describes Chemistry, Manufacturing, and Controls (CMC) work at PATH. It covers what CMC is and why it's important, where we work, our capabilities, and how interested parties can reach out to us for collaboration opportunities.

PATH conducted primary and secondary research to inform a regional priority assessment on diagnostics in sub-Saharan Africa, including desk research and review of global health publications, as well as direct discussions with subnational, national, and regional global health stakeholders.Findings from this assessment have been organized into a review of diagnostic priorities, in addition to a supply security landscape.

Respiratory syncytial virus (RSV) is a major, under–recognized public health problem causing more severe respiratory infections and hospitalizations in infants and young children each year than any other pathogen. New immunization tools are achieving licensure that could help change that.The opportunity to address this pervasive virus has never been better. To raise awareness, PATH and the World Health Organization are developing an evolving toolkit of communication materials that public health stakeholders and advocates can use to share information about RSV disease, new prevention tools, and delivery considerations.To learn more about the toolkit, visit the web page.Editable files are available upon request. Please contact us.

Final results of landmark study confirm two-thirds reduction in cases of malaria, including cases of severe malaria, and deaths from malaria, for RTS,S-drug combination over either intervention given alone in settings of highly seasonal malaria transmission. Results also showed the RTS,S vaccine has similar high efficacy to drugs in preventing malaria in highly seasonal transmission settings, and that overall reduction in malaria incidence likely “tops” 90% among children protected by bednets, vaccines, and drugs.